Kraft J, Grille W, Appelt M, Hossfeld D K, Eichelbaum M, Koslowski B, Quabeck K, Kuse R, Büchner T, Hiddemann W
Dept. of Medicine, Evangelisches Krankenhaus Essen-Werden, FRG.
Haematol Blood Transfus. 1990;33:566-70. doi: 10.1007/978-3-642-74643-7_103.
Previous investigations in animals and one retrospective study in man suggest that verapamil can prevent anthracycline-induced cardiomyopathy. In the following study, patients with acute myeloid leukemia (AML) treated with double induction and consolidation chemotherapy (AML COOP study 1986, [3]) were randomized in a group with and without accompanying low-dose oral verapamil treatment. Since July 1986, 64 patients have been included. Thirty patients have been evaluated for pre- and posttreatment cardiological investigations. So far, no significant difference in cardiotoxicity has been observed either between the verapamil and nonverapamil group or between the two induction chemotherapy regimens (TAD/TAD - TAD/HAM).
先前对动物的研究以及一项针对人类的回顾性研究表明，维拉帕米可预防蒽环类药物诱发的心肌病。在接下来的研究中，接受双联诱导和巩固化疗的急性髓系白血病（AML）患者（AML COOP研究1986，[3]）被随机分为两组，一组接受低剂量口服维拉帕米治疗，另一组不接受。自1986年7月以来，共纳入64例患者。30例患者接受了治疗前和治疗后的心脏检查评估。到目前为止，在维拉帕米组和非维拉帕米组之间，以及在两种诱导化疗方案（TAD/TAD - TAD/HAM）之间，均未观察到心脏毒性有显著差异。
